Русский
Possibility and prospects for the use of recombinant neutralizing monoclonal antibodies (bamlanivimab+etesevimab, sotrovimab) in patients with COVID-19
DOI: https://dx.doi.org/10.18565/pharmateca.2021.12.12-17
V.M. Tsvetov (1), I.S. Burashnikova (2), D.A. Sychev (3)
1) Federal Center for Cardiovascular Surgery, Chelyabinsk, Russia; 2) Kazan State Medical Academy – Branch Campus of the Russian Medical Academy of Continuous Professional Education, Kazan, Russia; 3) Russian Medical Academy of Continuous Professional Education, Moscow, Russia
Currently, there are prerequisites, such as data from phase 2 and 3 multicenter clinical trials, to recommend sotrovimab and bamlanivimab + etesevimab at the prehospital stage for outpatients positive for COVID-19 and in the first 10 days of symptom onset. Further research and long-term data from ongoing studies are required to confirm or disprove the initial results and understand how the emergence of new variants of viruses may affect the effectiveness of monoclonal antibodies that neutralize SARS-CoV-2.
Keywords: COVID-19, monoclonal antibodies
About the Autors
Corresponding author: Vitaly M. Tsvetov, Cand. Sci. (Med.), Clinical Pharmacologist, Federal Center for Cardiovascular Surgery, Chelyabinsk, Russia; SPIN-код: 3202-7659
Similar Articles
